Expert Comparison: Which Weight Loss Treatment Suits You?
Which Is Best Mounjaro or Wegovy for Prescription Weight Loss?
When comparing Mounjaro versus Wegovy for prescription weight loss, the key difference lies in their mechanisms of action rather than a simple "better or worse" assessment. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural hormone GLP-1 to reduce appetite and slow gastric emptying. Mounjaro contains tirzepatide, which works as a dual agonist targeting both GIP and GLP-1 receptors, potentially offering broader metabolic effects. Both are prescription-only medicines that require clinical assessment and must be used alongside a reduced-calorie diet and increased physical activity.
The decision between which is best, Mounjaro or Wegovy, often comes down to individual factors including your medical history, current medications, lifestyle preferences, and how you respond to treatment. Your prescriber will consider factors such as your BMI, existing health conditions, and previous weight loss attempts when recommending the most appropriate option. Both treatments follow similar dose escalation protocols over 16-20 weeks to reach maintenance levels, though the specific dosing schedules differ slightly between the two medications.
Wegovy Pricing and Value Through EverydayMeds
Understanding the cost structure helps inform your decision when comparing which is best, Mounjaro or Wegovy, for your budget and treatment duration. Wegovy pricing at EverydayMeds starts at £79.99 for the 0.25mg starter dose (using code FIRST40 for new customers), progressing through £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles provide convenience for the dose escalation phase, such as the Intro Duo (0.25mg & 0.5mg) for £169.99 or the Progress Trio (0.5mg, 1mg & 1.7mg) for £369.99.
For ongoing treatment, our Consistency bundles offer two pens of the same strength, whilst our Ultimate Stability Trio provides three 2.4mg maintenance pens for £649.99, ensuring uninterrupted supply. Returning customers can use code DOSE25 at checkout, with all prices including next-day cold-chain delivery once prescribed. The pricing structure reflects the pharmaceutical manufacturing costs and clinical oversight required for these prescription-only medicines supplied through our GPhC-registered pharmacy.
Clinical Evidence Supporting Both Treatments
When evaluating which is best, Mounjaro or Wegovy, both treatments demonstrate significant efficacy in clinical trials, though direct head-to-head comparisons are limited. The STEP clinical programme showed that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in STEP 1, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP 5 trial demonstrated sustained weight loss of approximately 15.2% at two years, whilst the SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events.
Mounjaro's SURMOUNT trials demonstrated weight loss results in their respective study populations, though comparing percentages directly between the programmes isn't appropriate due to different trial designs, patient populations, and endpoints. Both medications have undergone rigorous clinical evaluation and received MHRA approval for weight management in adults with appropriate BMI criteria, with NICE recommending Wegovy through TA875 guidance.
How Wegovy Works as a Weight Loss Treatment
Understanding the mechanism helps clarify which is best, Mounjaro or Wegovy, for your specific needs and expectations. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of glucagon-like peptide-1, a hormone naturally released by your intestines after eating. This medication works by binding to GLP-1 receptors in the brain's appetite control centres, specifically the hypothalamus, where it reduces hunger signals and increases feelings of satiety. The treatment also slows gastric emptying, meaning food stays in your stomach longer, contributing to prolonged fullness after smaller meals. Additionally, Wegovy may help reduce food cravings and the psychological drive to eat, particularly for high-calorie foods. These combined effects support weight loss when used alongside dietary changes and increased physical activity, as the medication doesn't replace the need for lifestyle modifications.
Streamlined Ordering Process at EverydayMeds
Accessing either treatment when deciding which is best, Mounjaro or Wegovy, begins with our comprehensive 3-minute online clinical assessment covering your medical history, current medications, weight loss goals, and lifestyle factors. Following submission, our qualified prescribers review your assessment within our standard 3 working days (or express 24-hour service), ensuring thorough evaluation of your suitability for prescription weight loss treatment. Once approved, your medication ships via next-day delivery using cold-chain, temperature-controlled packaging to maintain medication integrity from our GPhC-registered pharmacy (#9012878). Our prescribers provide ongoing support throughout your treatment journey, with regular check-ins and dose adjustment guidance as you progress through the escalation schedule. The process ensures clinical oversight whilst maintaining convenience and discretion for patients seeking professional weight management support.
Storage and Practical Considerations
Storage requirements represent a practical difference when comparing which is best, Mounjaro or Wegovy, particularly for frequent travellers or those with limited refrigeration access. Wegovy requires refrigeration at 2-8°C before first use but offers significant flexibility with up to 6 weeks storage at room temperature below 30°C once removed from the fridge, compared to Mounjaro's 21-day room temperature limit. Both medications use pre-filled injection pens (Wegovy's FlexTouch system) designed for once-weekly self-administration, typically into the thigh, upper arm, or abdomen. The dose escalation schedule for Wegovy follows a structured 16-week progression from 0.25mg to the 2.4mg maintenance dose, with each increase designed to minimise gastrointestinal side effects whilst optimising therapeutic benefit. Both treatments require consistent weekly administration on the same day each week for optimal effectiveness, with some flexibility if doses are missed within specific timeframes outlined in the patient information leaflets.
Dual Mechanism vs Single Target Approach
The fundamental difference when determining which is best, Mounjaro or Wegovy, lies in their receptor targeting strategies and resulting metabolic pathways. Wegovy's semaglutide specifically targets GLP-1 receptors, providing focused appetite suppression and gastric emptying effects that have been extensively studied in the STEP clinical programme. This single-target approach offers predictable pharmacology with well-established side effect profiles and drug interaction patterns. Mounjaro's tirzepatide operates as a dual agonist, simultaneously targeting both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, potentially offering broader metabolic effects including enhanced glucose control and different appetite regulation pathways.
The choice between single versus dual receptor targeting depends on individual patient factors including existing metabolic conditions, diabetes status, and response to previous treatments. Some patients may benefit from the focused approach of GLP-1-only targeting, whilst others might find advantage in the broader metabolic effects of dual agonism. Both mechanisms require the same lifestyle foundation of reduced-calorie diet and increased physical activity to achieve optimal results, as neither medication replaces the fundamental principles of energy balance for sustainable weight management.
Making Your Treatment Decision
Rather than declaring which is best, Mounjaro or Wegovy, the optimal choice depends on your individual circumstances, medical history, and treatment preferences evaluated during clinical assessment. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which treatment aligns best with your specific needs and goals. Start your assessment today using code FIRST40 for new customers or DOSE25 for returning patients, with expert guidance available throughout your weight management journey. Our clinical team provides ongoing support to ensure you receive the most appropriate treatment for your circumstances, with the flexibility to adjust approaches if needed based on your response and any side effects experienced.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
